| Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain |
2015-01-01 |
| EffRx–SEVERAL: investment, 201501 financing round CHF2.3m from existing investors |
2015-01-01 |
| GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors |
2015-01-01 |
| IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture |
2015-01-01 |
| Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures |
2015-01-01 |
| KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp |
2015-01-01 |
| Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) |
2015-01-01 |
| Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI |
2015-01-01 |
| Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI |
2015-01-01 |
| Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder |
2015-01-01 |
| Oncgnostics–MDxHealth: PCR technology, 201501– license ww non-excl for MSP technology for cervical cancer diagnostics to Oncgnostics |
2015-01-01 |
| Padlock Therapeutics–Evotec: drug discovery services, 201501–201703 extension of collab to deliver multiple PAD inhibitor development candidates |
2015-01-01 |
| Proteomedix–SEVERAL: investment, 201501 2nd closing of financing round Series B CHF1m bringing total round to CHF4.2m |
2015-01-01 |
| Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research |
2015-01-01 |
| VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB |
2015-01-01 |
| ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme |
2015-01-01 |
| Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG |
2014-12-18 |
| Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures |
2014-12-15 |
| Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF |
2014-12-15 |
| Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter |
2014-12-15 |
| Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures |
2014-12-15 |
| Nanolive–SEVERAL: investment, 201412 closing of 1st financing round |
2014-12-01 |
| Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana |
2014-12-01 |
| Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery |
2014-11-18 |
| Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech |
2014-10-16 |
| Abionic–SEVERAL: investment, 201410 financing round Series B CHF3.8m |
2014-10-01 |
| Corgenix Medical–Orgentec: investment, 201409–201503 acquisition of Corgenix for $16m in cash by Orgentec Diagnostika |
2014-09-01 |
| Ipsen–MHH: rec botulinum neurotoxin, 201409– collab r+d with Thomas Binz at Institute for Physiological Chemistry at MHH |
2014-09-01 |
| Riboxx–SEVERAL: investment, 201407–201501 crowdfunding €1m via Seedmatch |
2014-07-30 |
| Metrohm–Waters: chromatography s/w, 201407– collab product integration Empower CDS now can control Metrohm IC systems |
2014-07-17 |
| Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed |
2014-07-15 |
| AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie |
2014-07-01 |
| B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania |
2014-06-01 |
| Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US |
2014-05-01 |
| Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW |
2014-04-15 |
| Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17 |
2014-04-07 |
| Amal Therapeutics–Boehringer: investment, 201402 seed funding round from Boehringer Ingelheim Venture Fund + HTGF |
2014-02-20 |
| Amal Therapeutics–High-Tech Gründerfonds: investment, 201402 seed funding round from Boehringer Ingelheim Venture Fund + HTGF |
2014-02-20 |
| Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–SEVERAL: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex |
2014-01-01 |
| Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon |
2014-01-01 |
| Padlock Therapeutics–Evotec: drug discovery services, 201401–201412 collab to deliver multiple PAD inhibitor development candidates |
2014-01-01 |
| Peqlab–VWR International: investment, 2014 acquisition of Peqlab Biotechnologie GmbH inkl Clemens GmbH by VWR |
2014-01-01 |
| Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy |
2014-01-01 |
| Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m |
2014-01-01 |
| Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR |
2014-01-01 |
| Tusk Therapeutics–Droia: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures |
2014-01-01 |
| Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors |
2013-12-19 |
| Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax |
2013-11-21 |
| Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund |
2013-11-18 |
| Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America |
2013-10-02 |
| Gardner Denver–Kohlberg Kravis Roberts: investment, 201307 acquisition 100% for $3.9b incl assumption of debt |
2013-07-16 |
| Allecra Therapeutics–EMBL: investment, 201304 financing round Series A totalling €15m incl co-investor EMBL Ventures |
2013-04-18 |
| Allecra Therapeutics–Forbion: investment, 201304 financing round Series A totalling €15m incl co-lead investor Forbion |
2013-04-18 |
| Allecra Therapeutics–LCF Rothschild: investment, 201304 financing round Series A totalling €15m incl co-lead investor EdRIP |
2013-04-18 |
| Harrison Clinical Research–Synteract: investment, 201303 acquisition merger €na of HCR + Synteract into SynteractHCR |
2013-03-01 |
| ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management |
2013-01-01 |
| BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery |
2013-01-01 |
| Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif |
2013-01-01 |
| Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser |
2013-01-01 |
| PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch |
2012-12-04 |
| Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech |
2012-06-01 |
| Abionic–SEVERAL: investment, 201205 financing round Series A CHF3.5m from local VCs + business angels |
2012-05-01 |
| B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business |
2012-01-31 |
| Bayer–X-Chem: small-molecule drug discovery, 2012– collab research using DEX technology |
2012-01-01 |
| Gilupi–Viroad: investment, 2012 investment in connnection w strategic partnership making Viroad largest shareholder of Gilupi |
2012-01-01 |
| JnJ–Phenex: RORgt inhibitors, 2012– collab r+d up to $135m for chronic inflammatory + autoimmune disease w Janssen Biotech |
2012-01-01 |
| KBI BioPharma–Selexis: cell line development, 2012– supply service use of cell lines created using SUREtechnology platform by KBI |
2012-01-01 |
| Qtis/e–Xeltis: investment, 2012 merger of Qtis/e with Xeltis |
2012-01-01 |
| Selexys Pharmaceuticals–Novartis: investment, 201611 acquisition by Novartis for up to $665m upfront + acquisition + milestone payments |
2012-01-01 |
| Viroad–Gilupi: diagnostic device, 2012 collab strategic partnership incl investment making Viroad largest shareholder of Gilupi |
2012-01-01 |
| Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare |
2011-03-31 |
| Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures |
2011-03-31 |
| Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare |
2011-03-31 |
| Genoptix–Novartis: investment, 201701–201703 DIVESTMENT sale €na of Genoptix (excl biopharma business) to Ampersand + 1315 Capital + new managers |
2011-01-24 |
| JnJ–Molecular Partners: DARPins, 2011–201610 collab + license DARPin targeting IL-13 + IL-17 against pulmonary disease TERMINATED 10/16 |
2011-01-01 |
| Meiji Seika Kaisha–Newron: safinamide, 2011– license to develop + manufacture + commercialise safinamide in Asia to Meiji Seika Pharma |
2011-01-01 |
| Pfizer–Kohlberg Kravis Roberts: investment, 2011 acquisition of Capsugel from Pfizer by KKR |
2011-01-01 |
| Rebiotix–SEVERAL: investment, 2011 seed financing round $5m |
2011-01-01 |
| Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies |
2011-01-01 |
| Poxel–LCF Rothschild: investment, 201007 financing round Series A totalling €16m incl lead investor EdRIP |
2010-07-08 |
| Roche–Novimmune: therapeutic antibody, 201007– excl license to discover + develop ABs targeting IL-17 pathway for autoimmune diseases Genentech |
2010-07-01 |
| Probiodrug–Bellevue: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP |
2009-11-02 |
| Probiodrug–Biogen Idec: investment, 200911 financing round Series B totalling €36m incl new + co-investor Biogen Idec New Ventures |
2009-11-02 |
| Probiodrug–LCF Rothschild: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP |
2009-11-02 |
| Probiodrug–Life Sciences Partners: investment, 200911 financing round Series B totalling €36m incl new + co-investor LSP |
2009-11-02 |
| Denali Therapeutics–Evotec: CNS drug discovery, 201608 strategic collab existent |
2008-08-25 |
| Denali Therapeutics–Roche: LRRK2 inhibitors, 201608 license ww excl existent to develop + commericalize LRRK2 inhibitors from Genentech |
2008-08-25 |
| BioNTech–SEVERAL: investment, 2008 seed financing round |
2008-01-01 |
| Isoprime–Elementar: investment, 2008 acquisition of Isoprime Ltd by Elementar Analysensysteme GmbH |
2008-01-01 |
| Umetrics–MKS Instruments: investment, 2006 acquisition by MKS Instruments |
2006-01-01 |
| Actelion–Enamine: chemical compound library, 2005– collab supply of screening compound library to Actelion |
2005-01-01 |
| Chandler Instruments–AMETEK: investment, 2003 acquisition of Chandler Instruments by AMETEK |
2003-01-01 |
| Grabner Instruments–Chandler Instruments: investment, 2002 acquisition of Grabner by Chandler |
2002-01-01 |
| Biocentric–Hain Lifescience: molecular diagnostics, 2001– exclusive distributor of Hain products in France |
2001-01-01 |
| Selexis–SEVERAL: investment, 2001 seed financing CHF100k |
2001-01-01 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 30 31 32 
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
